You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美股異動|諾瓦瓦克斯醫藥漲超9% Q4淨虧損同比收窄 正加快研發新疫苗
格隆匯 02-27 23:26

諾瓦瓦克斯醫藥(NVAX.US)漲超9%,報8美元。消息面上,諾瓦瓦克斯醫藥第四季度財報顯示,淨虧損爲8100萬美元,而去年同期淨虧損爲1.783億美元,虧損收窄主要受益於新冠疫苗銷售和管理費用的減少。期內新冠疫苗銷售額僅爲4980萬美元,同比下降80.2%。面對市場需求疲軟,公司正寄望於與Sanofi的合作帶來的收入增長,同時加快推進新疫苗的研發。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account